-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
Ufo+WI1jh3gtlOch6l6z+yIbjOoOdIJ2HLBSnT/HK5TzIXZyCX56MB+nUVggmPVt
jGiWbdAr+5hcrA6aaclcbw==
UNITED
STATES OMB APPROVAL SECURITIES
AND EXCHANGE OMMISSION OMB Number: 3235-0059 Washington,
D.C. 20549 Expires: January 31, 2008 SCHEDULE
14A Estimated average burden
hours per response... 14
Proxy
Statement Pursuant to Section 14(a) of
the Securities Payment of Filing Fee (Check
the appropriate box):
Exchange Act of 1934 (Amendment No. )
Filed
by the Registrant x
Filed
by a Party other than the Registrant o
Check
the appropriate box:
o
Preliminary Proxy Statement
x
Definitive Proxy Statement
o
Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
o
Definitive
Additional Materials
o
Soliciting
Material Pursuant to Rule §240.14a-12
(Name of
Registrant as Specified In Its Charter)
x
No fee
required.
o
Fee computed
on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
1.
Title
of each class of securities to which transaction applies:
2.
Aggregate
number of securities to which transaction applies:
3.
Per unit
price or other underlying value of transaction computed pursuant to Exchange
Act Rule 0-11 (set forth the amount on which the filing fee is calculated
and state how it was determined):
4.
Proposed maximum aggregate
value of transaction:
5.
Total fee paid:
SEC 1913 (04-05)
Persons who are to respond to the collection of information
contained in this form are not required to respond unless the
form displays a currently valid OMB control number.
o
Fee paid
previously with preliminary materials.
o
Check
box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2)
and identify the filing for which the offsetting fee was paid previously.
Identify the previous filing by registration statement number, or the Form
or Schedule and the date of its filing.
1.
Amount Previously
Paid:
2.
Form, Schedule or
Registration Statement No.:
3.
Filing Party:
4.
Date Filed:
1. |
To elect the members of Class I of the Board of Directors to serve for the following three years or until their successors are elected and qualified; |
2. |
To amend the Companys Restated Certificate of Incorporation to increase the number of authorized shares of the Companys Common Stock to 200,000,000 shares; |
3. |
To approve the Companys 2006 Directors Stock Option Plan, to replace the 1996 Directors Stock Option Plan, which is expiring; |
4. |
To ratify appointment of Ernst & Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2006; and |
5. |
To transact such other business as may properly come before the Annual Meeting or any postponement or adjournment thereof. |
Name |
Age |
Principal Occupation/Position with the
Company |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
Thomas B.
Okarma, Ph.D., M.D. |
60 |
President and CEO |
||||||||
John P.
Walker |
57 |
Private Investor/Consultant |
||||||||
Patrick J.
Zenner |
59 |
Former President and CEO, Hoffmann La-Roche, Inc., North America |
Name |
Age |
Principal Occupation/Position with the
Company |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
Thomas D.
Kiley, Esq. |
62 |
Attorney-at-law |
||||||||
Edward V.
Fritzky |
55 |
Former Chairman, CEO and President, Immunex Corporation |
Name |
Age |
Principal Occupation/Position with the
Company |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
Alexander E. Barkas, Ph.D. |
58 |
Managing Member, Prospect Management Company, LLC, the General Partner of Prospect Venture Partners L.P.; Managing Member, Prospect Management
Co. II, LLC, the General Partner of Prospect Venture Partners II, L.P. and Prospect Associates II, L.P.; and Managing Member, Prospect Management Co.
III, LLC.; the General Partner of Prospect Venture Partners III, L.P. |
||||||||
Charles
J. Homcy, M.D. |
57 |
President and CEO, Portola Pharmaceuticals, Inc. |
(i) |
Twenty Thousand Dollars ($20,000) per year, plus an additional Ten Thousand Dollars ($10,000) for service as Chair of the Board or the Audit Committee and an additional Five Thousand Dollars ($5,000) for service as Chair of the Compensation Committee or the Nominating Committee of the Board; plus |
(ii) |
One Thousand Five Hundred Dollars ($1,500) for each regular or special Board meeting attended by such director in person, and Seven Hundred Fifty Dollars ($750) for each regular or special Board meeting attended by such director by telephone or videoconference; plus |
(iii) |
For members of the Audit Committee, Nominating Committee and the Compensation Committee of the Board, Seven Hundred Fifty Dollars ($750) for each meeting of either such committee attended by such director in person, and Two Hundred Fifty Dollars ($250) for each meeting of either such committee attended by such director by telephone or videoconference; plus |
(iv) |
Reimbursement for out-of-pocket expenses incurred in connection with attendance at meetings of the Board of Directors. |
Director |
Number of Shares Issued Under the 2002 Equity Incentive Plan |
Price Per Share |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
Barkas,
Alexander |
3,125 | $ | 6.40 | |||||||
Fritzky,
Edward |
1,875 | $ | 6.40 | |||||||
Kiley,
Thomas |
1,875 | $ | 6.40 | |||||||
Walker,
John |
2,187 | $ | 6.40 |
Director |
Number of Shares Subject to Options Granted under the 1996 Directors Plan |
Weighted Average Exercise Price Per Share |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
Barkas,
Alexander |
32,500 | $ | 6.40 | |||||||
Fritzky,
Edward |
22,500 | $ | 6.40 | |||||||
Homcy,
Charles |
45,000 | $ | 8.60 | |||||||
Kiley,
Thomas |
22,500 | $ | 6.40 | |||||||
Walker,
John |
22,500 | $ | 6.40 | |||||||
Zenner,
Patrick |
22,500 | $ | 6.40 |
Beneficial Ownership(1) |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Beneficial Owner |
Number of Shares |
Percent of Total |
|||||||||
Directors/Nominees and Named Executive Officers: |
|||||||||||
Alexander E.
Barkas, Ph.D.(2) |
360,724 | * |
|||||||||
Edward V.
Fritzky(3) |
178,045 | * |
|||||||||
Charles J.
Homcy, M.D.(4) |
| * |
|||||||||
Thomas D.
Kiley, Esq.(5) |
209,845 | * |
|||||||||
John P.
Walker(6) |
160,370 | * |
|||||||||
Patrick J.
Zenner(7) |
132,083 | * |
|||||||||
David J.
Earp, J.D., Ph.D.(8) |
376,855 | * |
|||||||||
David L.
Greenwood(9) |
771,028 | 1.17% |
|||||||||
Calvin B.
Harley, Ph.D.(10) |
458,539 | * |
|||||||||
Jane S.
Lebkowski, Ph.D.(11) |
410,193 | * |
|||||||||
Thomas B.
Okarma, Ph.D., M.D.(12) |
1,280,428 | 1.93% |
|||||||||
All directors
and executive officers as a group (12 persons) |
4,507,299 | 6.50% |
* |
Represents beneficial ownership of less than 1% of the Common
Stock. |
(1) |
Beneficial ownership is determined in accordance with the rules
of the SEC. In computing the number of shares beneficially owned by a person and the percentage of ownership of that person, shares of Common Stock
subject to options held by that person that are currently exercisable or exercisable within 60 days of February 21, 2006 are deemed outstanding. Such
shares, however, are not deemed outstanding for the purpose of computing the percentage ownership of each other person. The persons named in this
table, to the best of the Companys knowledge, have sole voting and investment power with respect to all shares of Common Stock shown as
beneficially owned by them, subject to community property laws where applicable and except as indicated in the other footnotes to this
table. |
(2) |
Includes 17,308 shares held directly by Alexander E. Barkas, 882
shares held by Lynda Wijcik, the spouse of Dr. Barkas, 17,056 shares held by the Barkas-Wijcik Trust under Agreement dated July 26, 1999, and 325,478
shares issuable upon the exercise of outstanding options held by Dr. Barkas exercisable within 60 days of February 21, 2006. |
(3) |
Represents 13,462 shares held directly by Edward V. Fritzky and
164,583 shares issuable upon the exercise of outstanding options held by Mr. Fritzky exercisable within 60 days of February 21, 2006. |
(4) |
Represents no shares issuable upon the exercise of outstanding
options held by Charles J. Homcy exercisable within 60 days of February 21, 2006. |
(5) |
Includes 63,462 shares held directly by Thomas D. Kiley, 9,705
shares held by the Kiley Family Partnership and 46,653 shares held by the Thomas D. Kiley and Nancy L.M. Kiley Revocable Trust under Agreement dated
August 7, 1981. Also includes 90,025 shares issuable upon the exercise of outstanding options held by Mr. Kiley exercisable within 60 days of February
21, 2006. |
(6) |
Includes 2,187 shares held directly by John P. Walker and
158,183 shares issuable upon the exercise of outstanding options held by Mr. Walker exercisable within 60 days of February 21, 2006. |
(7) |
Represents 132,083 shares issuable upon the exercise of
outstanding options held by Patrick J. Zenner exercisable within 60 days of February 21, 2006. |
(8) |
Includes 20,396 shares held directly by David J. Earp and
356,459 shares issuable upon the exercise of outstanding options held by Dr. Earp exercisable within 60 days of February 21, 2006. |
(9) |
Includes 16,977 shares held directly by David L. Greenwood and
754,051 shares issuable upon the exercise of outstanding options held by Mr. Greenwood exercisable within 60 days of February 21, 2006. |
(10) |
Includes 8,035 shares held directly by Calvin B. Harley and
450,504 shares issuable upon the exercise of outstanding options held by Dr. Harley exercisable within 60 days of February 21, 2006. |
(11) |
Includes 19,254 shares held directly by Jane S. Lebkowski and
390,939 shares issuable upon the exercise of outstanding options held by Dr. Lebkowski exercisable within 60 days of February 21, 2006. |
(12) |
Includes 31,575 shares held directly by Thomas B. Okarma and
1,248,853 shares issuable upon the exercise of outstanding options held by Dr. Okarma exercisable within 60 days of February 21, 2006. |
Number of securities to be issued upon exercise of outstanding options, warrants and rights |
Weighted-average exercise price of outstanding options, warrants and rights |
Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
(a) |
(b) |
(c) |
|||||||||||
Equity
compensation plans approved by security holders(1) |
7,786,707 | $ | 7.98 | 5,359,954 | (2),(3) | |||||||||
Equity
compensation plans not approved by security holders |
5,335,436 | (4) | $ | 11.02 | | |||||||||
Total |
13,122,143 | $ | 9.22 | 5,359,954 |
(1) |
Includes the 1992 Stock Option Plan, the 1996 Directors
Stock Option Plan and the 2002 Equity Incentive Plan. |
(2) |
Includes 312,498 shares of common stock reserved for issuance
under Gerons 1996 Employee Stock Purchase Plan. |
(3) |
Does not include future automatic annual increases under
Gerons 2002 Equity Incentive Plan. The maximum number of shares to be reserved will automatically increase on each anniversary date of the Board
of Directors adoption of the 2002 Plan during the term of the 2002 Plan by the least of (i) 2,000,000 shares, (ii) 4% of the Companys
outstanding common stock as of such anniversary date, or (iii) a lesser amount determined by the Board. |
(4) |
Represents outstanding warrants issued in conjunction with
equity financing transactions, consulting services agreements and license agreements with research institutions. For further details, see Note 12 of
Notes to Consolidated Financial Statements of the Companys Annual Report on Form 10-K filed with the SEC on March 1, 2006. |
Long-Term Compensation Awards |
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Annual Compensation |
||||||||||||||||||||||||||
Name and Principal Position |
Year |
Salary($) |
Bonus($)(1) |
Other Annual Compensation($)(2) |
Securities Underlying Options(#) |
All Other Compensation($)(3) |
||||||||||||||||||||
Thomas
B. Okarma, M.D., Ph.D. |
2005 | $ | 445,000 | $ | 213,597 | $ | 0 | 110,000 | $ | 0 | ||||||||||||||||
President and Chief |
2004 | 441,000 | 255,003 | 0 | 100,000 | 0 | ||||||||||||||||||||
Executive Officer |
2003 | 420,000 | 268,230 | 42,000 | 100,000 | 0 | ||||||||||||||||||||
David
L. Greenwood |
2005 | 350,000 | 137,802 | 0 | 85,000 | 18,000 | ||||||||||||||||||||
Executive Vice President, |
2004 | 340,389 | 151,204 | 0 | 75,000 | 16,000 | ||||||||||||||||||||
Chief
Financial Officer, |
2003 | 310,010 | 153,040 | 31,000 | 75,000 | 14,000 | ||||||||||||||||||||
Secretary and Treasurer |
||||||||||||||||||||||||||
David
J. Earp, J.D., Ph.D. |
2005 | 275,000 | 96,246 | 0 | 60,000 | 14,000 | ||||||||||||||||||||
Senior
Vice President of |
2004 | 267,583 | 103,850 | 0 | 50,000 | 13,000 | ||||||||||||||||||||
Business Development and |
2003 | 243,800 | 103,290 | 24,380 | 37,500 | 12,000 | ||||||||||||||||||||
Chief
Patent Counsel |
||||||||||||||||||||||||||
Jane
S. Lebkowski, Ph.D. |
2005 | 275,000 | 90,746 | 0 | 60,000 | 18,000 | ||||||||||||||||||||
Senior
Vice President of |
2004 | 267,170 | 103,127 | 0 | 50,000 | 13,000 | ||||||||||||||||||||
Regenerative Medicine |
2003 | 235,400 | 99,730 | 23,540 | 37,500 | 12,000 | ||||||||||||||||||||
Calvin
B. Harley, Ph.D. |
2005 | 272,000 | 78,056 | 0 | 60,000 | 18,000 | ||||||||||||||||||||
Vice
President and Chief |
2004 | 270,110 | 87,621 | 0 | 37,500 | 10,596 | ||||||||||||||||||||
Scientific Officer |
2003 | 257,250 | 74,260 | 25,725 | 37,500 | 14,000 |
(1) |
The Company paid the 2005 and 2004 bonuses with shares of the Companys Common Stock equal to the value of each employees bonus amount at an average price of $8.50 and $8.82 per share, respectively. |
(2) |
The amounts in this column consist of retention bonuses paid in January 2004. Following a restructuring in January 2003, the Company entered into employment agreements with its remaining executive officers and certain other employees. Among other provisions, the employment agreements provided for the Company to pay on January 5, 2004 a retention bonus equal to 10% of the employees 2003 annual salary. The Company paid the retention bonuses with shares of the Companys Common Stock equal to the value of each employees bonus amount at a price of $10.10 per share. See information about the employment agreements under Employment, Severance and Change of Control Agreements on page 17. |
(3) |
The amounts in this column consist of matching contributions made by the Company under the Geron 401(k) Plan, a plan providing for broad-based employee participation. Under the 401(k) Plan, participating employees may contribute up to the annual Internal Revenue Service contribution limit. In December 2005, 2004 and 2003, the Board of Directors approved a matching contribution equal to 100% of each employees annual contributions during 2005, 2004 and 2003, respectively. The matching contribution is invested in the Companys Common Stock and vests ratably over four years for each year of service completed by the employee, commencing from the date of hire, until it is fully vested when the employee has completed four years of service. The 2005 contributions were made on January 6, 2006 at a market value of $8.50 per share. |
Individual Grants |
|||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Potential Realizable Value at Assumed Annual Rates of Stock Price Appreciation for Option Term(4) |
|||||||||||||||||||||||||||
Name |
Number of Shares Underlying Options Granted(#)(1) |
Percent of Total Options Granted to Employees in Fiscal Year(2) |
Exercise or Base Price ($/sh)(3) |
Expiration Date |
5%($) |
10%($) |
|||||||||||||||||||||
Thomas
B. Okarma, Ph.D., M.D. |
110,000 | 7.9 | % | $ | 6.40 | 5/6/15 | $ | 442,742 | $ | 1,121,995 | |||||||||||||||||
David
L. Greenwood |
85,000 | 6.1 | % | $ | 6.40 | 5/6/15 | $ | 342,119 | $ | 866,996 | |||||||||||||||||
David
J. Earp, Ph.D., J.D. |
60,000 | 4.3 | % | $ | 6.40 | 5/6/15 | $ | 241,496 | $ | 611,997 | |||||||||||||||||
Jane
S. Lebkowski, Ph.D. |
60,000 | 4.3 | % | $ | 6.40 | 5/6/15 | $ | 241,496 | $ | 611,997 | |||||||||||||||||
Calvin
B. Harley, Ph.D. |
60,000 | 4.3 | % | $ | 6.40 | 5/6/15 | $ | 241,496 | $ | 611,997 |
(1) |
Each of these stock options, which were granted under the 2002 Equity Incentive Plan, is exercisable in a series of installments measured from the vesting commencement date generally over 48 months, provided that each Named Executive Officer continues to provide services to the Company. In the event of certain transactions involving a change in control of the Company, the options will vest in full. The maximum term of each option grant is ten years from the date of grant. |
(2) |
Based on an aggregate of 1,393,537 options granted by the Company under the 2002 Equity Incentive Plan in the year ended December 31, 2005 to all employees of the Company, including the Named Executive Officers. |
(3) |
Exercise price is equal to the closing sales price of the Common Stock underlying the stock option on the grant date as reported on the Nasdaq National Market. |
(4) |
The 5% and 10% assumed annual rates of compounded stock price appreciation are mandated by the SEC. There is no assurance provided to any executive officer or any other holder of the Companys securities that the actual stock price appreciation over the ten year option term will be at the assumed 5% and 10% levels or at any other defined level. Unless the market price of the Common Stock appreciates over the option term, no value will be realized from the option grants made to the executive officers. |
Number of Securities Underlying Unexercised Options at Fiscal Year-End(2)(#) |
Value of Unexercised in-the-Money Options at Fiscal Year-End(3)($) |
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Name |
Shares Acquired on Exercise(#) |
Value Realized(1)($) |
Exercisable |
Unexercisable |
Exercisable |
Unexercisable |
|||||||||||||||||||||
Thomas
B. Okarma, Ph.D., M.D. |
| $ | | 1,200,313 | 274,687 | $ | 2,437,581 | $ | 620,089 | ||||||||||||||||||
David
L. Greenwood |
30,000 | 200,700 | 719,572 | 181,769 | 1,672,938 | 471,018 | |||||||||||||||||||||
David
J. Earp, J.D., Ph.D. |
| | 338,699 | 108,801 | 415,243 | 251,682 | |||||||||||||||||||||
Jane
S. Lebkowski, Ph.D. |
| | 372,762 | 109,738 | 610,518 | 256,227 | |||||||||||||||||||||
Calvin
B. Harley, Ph.D. |
25,000 | 146,575 | 433,421 | 101,873 | 1,101,992 | 248,178 |
(1) |
Fair market value of the Companys Common Stock on the date of exercise (based on the closing sales price reported on the Nasdaq National Market or the actual sales price if the shares were sold by the optionee on the same date) less the exercise price. |
(2) |
These stock options, which were granted either under the 2002 Equity Incentive Plan or the 1992 Stock Option Plan, are exercisable in a series of installments measured from the vesting commencement date generally over 48 months, provided that each Named Executive Officer continues to provide services to the Company. In the event of certain transactions involving a change in control of the Company, the options will vest in full. The maximum term of each option grant is ten years from the date of grant. |
(3) |
Based on the closing sales price of the Common Stock as of December 30, 2005, quoted on the Nasdaq National Market ($8.61 per share), minus the per share exercise price, multiplied by the number of shares underlying the option. |
|
Base salary: Base salary ranges are reviewed
annually and adjustments are made at the beginning of the fiscal year to reflect changes in job description or market conditions. When establishing or
reviewing compensation levels for each executive officer, the Committee considers numerous factors, including the qualifications of the executive, his
or her level of relevant experience, specific operating roles and duties and strategic goals for which the executive has responsibility. |
|
Annual incentive awards: Bonuses are awarded
on a discretionary basis, usually following the Companys fiscal year-end, and are based on the achievement of corporate and individual goals set
by the Board and the Companys Chief Executive Officer at the beginning of the year, as well as the financial condition of the
Company. |
|
Long-term incentive compensation: The Company
has used the grant of options under its 2002 Equity Incentive Plan to underscore the common interests of stockholders and management. Options granted
to executive officers are intended to provide a continuing financial incentive to maximize long-term value to stockholders and to make each
executives total compensation opportunity competitive. In addition, because stock options generally become exercisable over a period of several
years, options encourage executives to remain in the long-term employ of the Company. In determining the size of an option to be granted to an
executive officer, the Committee takes into account an officers position and level of responsibility within the Company, the officers
existing stock and option holdings, and the potential reward to the officer if the stock price appreciates in the public market. |
(1) |
This Section is not soliciting material, is not
deemed filed with the SEC and is not to be incorporated by reference in any filing of the Company under the Securities Act of 1933, as
amended (the Securities Act), or the Securities Exchange Act of 1934, as amended (the Exchange Act), whether made before or after the date hereof and
irrespective of any general incorporation language in any such filing. |
|
closing of a public financing resulting in net proceeds of $58.0 million; |
|
continued strengthening of the Companys intellectual property position; |
|
formation of two joint ventures to enable separate funding and focused attention for nuclear transfer and telomerase activation applications; |
|
establishment of a research, license and collaboration agreement
with Merck & Co., Inc. for the telomerase cancer vaccine which included an exercise of a warrant to purchase Geron stock with aggregate proceeds of
$18.0 million; |
|
commencement of the Companys first clinical trial for GRN163L; |
|
published animal results for GRNOPC1, the Companys first human embryonic stem cell-derived therapy; and |
|
continued progress in development of other human embryonic stem cell programs. |
(1) |
This Section is not soliciting material, is not deemed filed with the SEC and is not to be incorporated by reference in any filing of the Company under the Securities Act, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. |
(2) |
Shows the cumulative total return on investment assuming an investment of $100 in each of the Company, the Nasdaq-US and the Nasdaq-Pharmaceutical on December 29, 2000. The cumulative total return on the Companys stock has been computed based on a price of $15.438 per share, the price at which the Companys shares closed on December 29, 2000. |
|
maintenance by management of the reliability and integrity of the accounting policies and financial reporting and financial disclosure practices of the Company; |
|
establishment and maintenance by management of processes to assure that an adequate system of internal controls is functioning within the Company; and |
|
retention and termination of the independent auditors. |
1) |
The Audit Committee has reviewed and discussed the audited financial statements of the Company as of and for the year ended December 31, 2005 with management and the independent auditors. |
2) |
The Audit Committee has discussed with the independent auditors the matters required to be discussed by Statement on Auditing Standards No. 61 (Communication with Audit Committees), other professional standards, membership provisions of the SEC Practice Session, and other SEC rules, as currently in effect. |
3) |
The Audit Committee has received the written disclosures and the letter from the independent auditors required by Independence Standards Board Standard No. 1 (Independence Discussions with Audit Committees), as currently in effect, and it has discussed with the auditors their independence from the Company. |
4) |
The Audit Committee has considered whether the independent auditors provision of non-audit services to the Company is compatible with maintaining the auditors independence. |
(1) |
This Section is not soliciting material is not deemed filed with the SEC and is not to be incorporated by reference in any filing of the Company under the Securities Act, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. |
Fiscal Year Ended December 31, 2005 |
Fiscal Year Ended December 31, 2004 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Audit
Fees(1) |
$ | 450,054 | $ | 420,204 | ||||||
Audit Related
Fees(2) |
5,330 | 60,066 | ||||||||
Tax
Fees |
29,018 | 13,943 | ||||||||
All Other
Fees |
1,225 | 1,500 |
(1) |
Audit Fees include the audit of our annual consolidated financial statements, reviews of our quarterly consolidated financial statements included in our Quarterly Reports on Forms 10-Q and services provided in connection with SEC filings, including consents and comfort letters. |
(2) |
Audit Related Fees include consultations on accounting and auditing matters related to proposed transactions and consultation on compliance requirements related to Section 404 of the Sarbanes-Oxley Act of 2002. |
(i) |
experience in corporate management, such as serving as an officer or former officer of a publicly held company, and a general understanding of marketing, finance and other elements relevant to the success of a publicly traded company in todays business environment; |
(ii) |
experience in the Companys industry and with relevant social policy concerns; |
(iii) |
experience as a board member of another publicly held company; |
(iv) |
academic expertise in an area of the Companys operations; and |
(v) |
practical and mature business judgment, including ability to make independent analytical inquiries. |
(A) Class of Stock. The Corporation is
authorized to issue two classes of stock to be designated, respectively, Common Stock and Preferred Stock. The total number of
shares which the Corporation is authorized to issue is Two Hundred Three Million (203,000,000) shares. Two Hundred Million (200,000,000) shares shall
be Common Stock, par value $0.001 per share, and Three Million (3,000,000) shares shall be Preferred Stock, par value $0.001 per
share. |
1. |
Purposes of the Plan. |
2. |
Definitions. |
(a) |
Board shall mean the Board of Directors of the Company. |
(b) |
Code shall mean the Internal Revenue Code of 1986, as amended. |
(c) |
Common Stock shall mean the Common Stock of the Company. |
(d) |
Company shall mean Geron Corporation, a Delaware corporation. |
(e) |
Continuous Status as a Director shall mean the absence of any interruption or termination of service as a Director. |
(f) |
Director shall mean a member of the Board. |
(g) |
Employee shall mean any person, including
officers and directors, employed by the Company or any Parent or Subsidiary of the Company. The payment of a directors fee by the Company shall
not be sufficient in and of itself to constitute employment by the Company. |
(h) |
Exchange Act shall mean the Securities Exchange Act of 1934, as amended. |
(i) |
Option shall mean a stock option granted
pursuant to the Plan. All Options shall be nonqualified stock options (i.e., options that are not intended to qualify as incentive stock options under
Section 422 of the Code). |
(j) |
Optioned Stock shall mean the Common Stock subject to an Option. |
(k) |
Optionee shall mean an Outside Director who receives an Option. |
(l) |
Outside Director shall mean a Director who is not an Employee. |
(m) |
Parent shall mean a parent corporation, whether now or hereafter existing, as defined in Section 424(e) of the Code. |
(n) |
Plan shall mean this 2006 Directors Stock Option Plan. |
(o) |
Share shall mean a share of the Common Stock, as adjusted in accordance with Section 11 of the Plan. |
(p) |
Subsidiary shall mean a subsidiary corporation, whether now or hereafter existing, as defined in Section 424(f) of the Code. |
3. |
Stock Subject to the Plan. |
4. |
Administration of and Grants of Options under the Plan. |
(a) |
Administrator. Except as otherwise required herein, the Plan shall be administered by the Board. |
(b) |
Procedure for Grants. All grants of Options hereunder
shall be automatic and non-discretionary and shall be made strictly in accordance with the following provisions: |
(i) |
No person shall have any discretion to select which Outside
Directors shall be granted Options or to determine the number of Shares to be covered by Options granted to Outside Directors. |
(ii) |
Each Outside Director shall be automatically granted an Option
to purchase 45,000 Shares (the First Option) on the date on which such person first becomes an Outside Director, whether through election
by the stockholders of the Company or appointment by the Board to fill a vacancy. |
(iii) |
Each Outside Director, other than the Chairman of the Board or
an Outside Director whose First Option is being granted on the date of the Annual Meeting of the Companys stockholders, shall be automatically
granted an Option to purchase 20,000 Shares (a Subsequent Option) on the date of the Annual Meeting of the Companys stockholders in
each year of his service. The Subsequent Option granted to the Chairman of the Board under this Section 4(b)(iii) shall be an Option to purchase 40,000
Shares. |
(iv) |
Each Outside Director who is appointed to serve on the Audit
Committee, the Compensation Committee, Nominating Committee or another standing committee of the Board designated by the Board as qualifying for such
grant, shall each be automatically granted an Option to purchase 2,500 Shares (a First Committee Service Option) on the date on which such
person first is appointed to serve on such standing committee. |
(v) |
Each Outside Director, other than the Chairman of the Audit
Committee, Compensation Committee, Nominating Committee or another so designated standing committee of the Board or an Outside Director whose First
Committee Service Option is being granted on the date of the Annual Meeting of the Companys stockholders, who continues to serve on the Audit
Committee, the Compensation Committee, Nominating Committee or another so designated standing committee of the Board, shall be automatically granted an
Option to purchase 2,500 Shares (a Subsequent Committee Service Option) on the date of the Annual Meeting of the Companys
stockholders. |
(vi) |
Each Outside Director, who serves as a Chairman of the Audit
Committee, Compensation Committee or Nominating Committee or another standing committee of the Board designated by the Board as qualifying for such
grant, shall be automatically granted an Option to purchase Shares (a Committee Chair Service Option) on the date of the Annual Meeting of
the Companys stockholders. The Committee Chair Service Option granted to the Audit Committee Chairman under this Section 4(b)(vi) shall be an
Option to purchase 10,000 Shares. The Committee Chair Service Option granted to the Compensation Committee Chairman and Nominating Committee Chairman
under this Section 4(b)(vi) shall each be an Option to purchase 5,000 Shares. |
(vii) |
Notwithstanding the provisions of subsections (ii), (iii), (iv),
(v) and (vi) hereof, in the event that a grant would cause the number of Shares subject to outstanding Options plus the number of Shares |
previously purchased upon exercise of Options to exceed the Pool, then each such automatic grant shall be for that number of Shares determined by dividing the total number of Shares remaining available for grant by the number of Outside Directors receiving an Option on such date on the automatic grant date. Any further grants shall then be deferred until such time, if any, as additional Shares become available for grant under the Plan through action of the shareholders to increase the number of Shares which may be issued under the Plan or through cancellation or expiration of Options previously granted hereunder. |
(viii) |
The terms of each First Option granted hereunder shall be as follows: |
(1) |
the First Option shall be exercisable only while the Outside Director remains a Director of the Company, except as set forth in Section 9 hereof. |
(2) |
the exercise price per Share shall be 100% of the fair market value per Share on the date of grant of the First Option, determined in accordance with Section 8 hereof. |
(3) |
the First Option shall become exercisable in installments cumulatively as to 33 1/3% of the Shares subject to the First Option on each of the first, second and third anniversaries of the date of grant of the First Option. |
(ix) |
The terms of each Subsequent Option granted hereunder shall be as follows: |
(1) |
the Subsequent Option shall be exercisable only while the Outside Director remains a Director of the Company, except as set forth in Section 9 hereof. |
(2) |
the exercise price per Share shall be 100% of the fair market value per Share on the date of grant of the Subsequent Option, determined in accordance with Section 8 hereof. |
(3) |
the Subsequent Option shall become exercisable as to one hundred percent (100%) of the Shares subject to the Subsequent Option on the date of grant of the Subsequent Option. |
(x) |
The terms of each First Committee Service Option granted hereunder shall be as follows: |
(1) |
the First Committee Service Option shall be exercisable only while the Outside Director remains a Director of the Company, except as set forth in Section 9 hereof. |
(2) |
the exercise price per Share shall be 100% of the fair market value per Share on the date of grant of the First Committee Service Option, determined in accordance with Section 8 hereof. |
(3) |
the First Committee Service Option shall become exercisable as to one hundred percent (100%) of the Shares subject to the First Committee Service Option on the date of grant of the First Committee Service Option. |
(xi) |
The terms of each Subsequent Committee Service Option granted hereunder shall be as follows: |
(1) |
the Subsequent Committee Service Option shall be exercisable only while the Outside Director remains a Director of the Company, except as set forth in Section 9 hereof. |
(2) |
the exercise price per Share shall be 100% of the fair market value per Share on the date of grant of the Subsequent Committee Service Option, determined in accordance with Section 8 hereof. |
(3) |
the Subsequent Committee Service Option shall become exercisable as to one hundred percent (100%) of the Shares subject to the Subsequent Committee Service Option on the date of grant of the Subsequent Committee Service Option. |
(xii) |
The terms of each Committee Chair Service Option granted hereunder shall be as follows: |
(1) |
the Committee Chair Service Option shall be exercisable only while the Outside Director remains a Director of the Company, except as set forth in Section 9 hereof. |
(2) |
the exercise price per Share shall be 100% of the fair market value per Share on the date of grant of the Committee Chair Service Option, determined in accordance with Section 8 hereof. |
(3) |
the Committee Chair Service Option shall become exercisable as to one hundred percent (100%) of the Shares subject to the Committee Chair Service Option on the date of grant of the Committee Chair Service Option. |
(c) |
Powers of the Board. Subject to the provisions and restrictions of the Plan, the Board shall have the authority, in its discretion: (i) to determine, upon review of relevant information and in accordance with Section 8(b) of the Plan, the fair market value of the Common Stock; (ii) to determine the exercise price per share of Options to be granted, which exercise price shall be determined in accordance with Section 8(a) of the Plan; (iii) to interpret the Plan; (iv) to prescribe, amend and rescind rules and regulations relating to the Plan; (v) to authorize any person to execute on behalf of the Company any instrument required to effectuate the grant of an Option previously granted hereunder; and (vi) to make all other determinations deemed necessary or advisable for the administration of the Plan. |
(d) |
Effect of Boards Decision. All decisions, determinations and interpretations of the Board shall be final and binding on all Optionees and any other holders of any Options granted under the Plan. |
(e) |
Suspension or Termination of Option. If the President or his or her designee reasonably believes that an Optionee has committed an act of misconduct, the President may suspend the Optionees right to exercise any option pending a determination by the Board of Directors (excluding the Outside Director accused of such misconduct). If the Board of Directors (excluding the Outside Director accused of such misconduct) determines an Optionee has committed an act of embezzlement, fraud, dishonesty, nonpayment of an obligation owed to the Company, breach of fiduciary duty or deliberate disregard of the Company rules resulting in loss, damage or injury to the Company, or if an Optionee makes an unauthorized disclosure of any Company trade secret or confidential information, engages in any conduct constituting unfair competition, induces any Company customer to breach a contract with the Company or induces any principal for whom the Company acts as agent to terminate such agency relationship, neither the Optionee nor his or her estate shall be entitled to exercise any option whatsoever. In making such determination, the Board of Directors (excluding the Outside Director accused of such misconduct) shall act fairly and shall give the Optionee an opportunity to appear and present evidence on Optionees behalf at a hearing before the Board or a committee of the Board. |
5. |
Eligibility. |
6. |
Term of Plan; Effective Date. |
7. |
Term of Options. |
8. |
Exercise Price and Consideration. |
(a) |
Exercise Price. The per Share exercise price for the
Shares to be issued pursuant to exercise of an Option shall be 100% of the fair market value per Share on the date of grant of the Option. |
(b) |
Fair Market Value. The fair market value shall be
determined by the Board; provided, however, that where there is a public market for the Common Stock, the fair market value per Share shall be the mean
of the bid and asked prices of the Common Stock in the over-the-counter market on the date of grant, as reported in The Wall Street Journal (or, if not
so reported, as otherwise reported by the National Association of Securities Dealers Automated Quotation (Nasdaq) System) or, in the event
the Common Stock is traded on the Nasdaq National Market or listed on a stock exchange, the fair market value per Share shall be the closing price on
such system or exchange on the date of grant of the Option, as reported in The Wall Street Journal. With respect to any Options granted hereunder
concurrently with the initial effectiveness of the Plan, the fair market value shall be the Price to Public as set forth in the final prospectus
relating to such initial public offering. |
(c) |
Form of Consideration. The consideration to be paid for
the Shares to be issued upon exercise of an Option shall consist entirely of cash, check, other Shares of Common Stock having a fair market value on
the date of surrender equal to the aggregate exercise price of the Shares as to which said Option shall be exercised (which, if acquired from the
Company, shall have been held for at least six months), or any combination of such methods of payment and/or any other consideration or method of
payment as shall be permitted under applicable corporate law. |
9. |
Exercise of Option. |
(a) |
Procedure for Exercise; Rights as a Stockholder. Any
Option granted hereunder shall be exercisable at such times as are set forth in Section 4(b) hereof; provided, however, that no Options shall be
exercisable prior to stockholder approval of the Plan in accordance with Section 17 hereof has been obtained. |
(b) |
Termination of Status as a Director. If an Outside
Director ceases to serve as a Director, he or she may, but only within ninety (90) days after the date he or she ceases to be a Director of the
Company, exercise his or her Option to the extent that he or she was entitled to exercise it at the date of such termination. Notwithstanding the
foregoing, in no event may the Option be exercised after its term set forth in Section 7 has expired. To the extent that such Outside Director was not
entitled to exercise an Option at the date of such termination, or does not exercise such Option (which he or she was entitled to exercise) within the
time specified herein, the Option shall terminate. |
(c) |
Disability of Optionee. Notwithstanding Section 9(b)
above, in the event a Director is unable to continue his or her service as a Director of the Company as a result of his or her total and permanent
disability (as defined in Section 22(e)(3) of the Internal Revenue Code), he or she may, but only within twenty-four (24) months from the date of such
termination, exercise his or her Option to the extent of the right to exercise that would have accrued had the Optionee remained in Continuous Status
as Director for thirty-six (36) months (or such lesser period of time as is determined by the Board) after the date of such termination.
Notwithstanding the foregoing, in no event may the Option be exercised after its term set forth in Section 7 has expired. To the extent that he or she
does not exercise such Option (which he or she was entitled to exercise) within the time specified herein, the Option shall terminate. |
(d) |
Death of Optionee. In the event of the death of an Optionee: |
(i) |
During the term of the Option, if the Optionee is, at the time
of his or her death, a Director of the Company and has been in Continuous Status as a Director since the date of grant of the Option, the Option may be
exercised, at any time within twenty-four (24) months following the date of death, by the Optionees estate or by a person who acquired the right
to exercise the Option by bequest or inheritance, but only to the extent of the right to exercise that would have accrued had the Optionee continued
living and remained in Continuous Status as Director for thirty-six (36) months (or such lesser period of time as is determined by the Board) after the
date of death. Notwithstanding the foregoing, in no event may the Option be exercised after its term set forth in Section 7 has expired. |
(ii) |
Within three (3) months after the termination of Continuous
Status as a Director, the Option may be exercised, at any time within six (6) months following the date of death, by the Optionees estate or by a
person who acquired the right to exercise the Option by bequest or inheritance, but only to the extent of the right to exercise that had accrued at the
date of termination. Notwithstanding the foregoing, in no event may the option be exercised after its term set forth in Section 7 has
expired. |
10. |
Nontransferability of Options. |
11. |
Adjustments Upon Changes in Capitalization; Corporate Transactions. |
(a) |
Adjustment. Subject to any required action by the
stockholders of the Company, the number of shares of Common Stock covered by each outstanding Option, the number of shares of Common Stock which have
been authorized for issuance under the Plan but as to which no Options have yet been granted or which have been returned to the Plan upon cancellation
or expiration of an Option, and the number of shares of Common Stock to be granted under the provisions set forth in Section 4 of the Plan, as well as
the price per share of Common Stock covered by each such outstanding Option, shall be proportionately adjusted for any increase or decrease in the
number of issued shares of Common Stock resulting from a stock split, reverse stock split, stock dividend, combination or reclassification of the
Common Stock, or any other increase or decrease in the number of issued shares of Common Stock effected without receipt of consideration by the
Company; provided, however, that conversion of any convertible securities of the Company shall not be deemed to have been effected without
receipt of consideration. Such adjustment shall be made by the Board, whose determination in that respect shall be final, binding and conclusive.
Except as expressly provided herein, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any
class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number or price of shares of Common Stock subject to an
Option. |
(b) |
Corporate Transactions. In the event of (i) a dissolution or liquidation of the Company, (ii) a sale of all or substantially all of the Companys assets, (iii) a merger or consolidation in which the Company is not the surviving corporation, or (iv) any other capital reorganization in which more than fifty percent (50%) of the shares of the Company entitled to vote are exchanged, the Company shall give to the Eligible Director, at the time of adoption of the plan for liquidation, dissolution, sale, merger, consolidation or reorganization, a reasonable time thereafter within which to exercise the Option, including Shares as to which the Option would not be otherwise exercisable, prior to the effectiveness of such liquidation, dissolution, sale, merger, consolidation or reorganization, at the end of which time the Option shall terminate. |
12. |
Time of Granting Options. |
13. |
Amendment and Termination of the Plan. |
(a) |
Amendment and Termination. The Board may amend or terminate the Plan from time to time in such respects as the Board may deem advisable; provided that, to the extent necessary and desirable to comply with any applicable law or regulation, the Company shall obtain approval of the stockholders of the Company of Plan amendments to the extent and in the manner required by such law or regulation. |
(b) |
Effect of Amendment or Termination. Any such amendment or termination of the Plan that would impair the rights of any Optionee shall not affect Options already granted to such Optionee and such Options shall remain in full force and effect as if this Plan had not been amended or terminated, unless mutually agreed otherwise between the Optionee and the Board, which agreement must be in writing and signed by the Optionee and the Company. |
14. |
Conditions Upon Issuance of Shares. |
15. |
Reservation of Shares. |
16. |
Option Agreement. |
17. |
Stockholder Approval. |
|
||
|
||
|
||
|
Please Detach Here |
|
|
|
|||||||||||||||||||||||
|
1. Election of Class I Directors. |
|
|
||||||||||||||||||||
|
|
|
|
|
|
|
|||||||||||||||||
|
o |
FOR the nominees |
o |
WITHHOLD authority to vote |
x |
Please mark your votes |
|||||||||||||||||
(except as indicated) |
for the nominees |
as in this example. |
|||||||||||||||||||||
|
|
|
|||||||||||||||||||||
|
Nominees: Thomas B. Okarma, Ph.D., M.D., John P. Walker and Patrick J. Zenner |
|
|||||||||||||||||||||
|
|
|
|||||||||||||||||||||
|
If you wish to withhold authority to vote for any individual nominee, strike a line through that individuals name. |
||||||||||||||||||||||
|
|
|
|
|
|
|
|||||||||||||||||
|
2. |
To amend the Companys Restated Certificate of Incorporation to increase the number of authorized shares of the Companys Common Stock to 200,000,000 shares. |
4. |
To ratify appointment of Ernst & Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2006. |
|||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
|
o |
FOR |
o |
AGAINST |
o |
ABSTAIN |
|
o |
FOR |
o |
AGAINST |
o |
ABSTAIN |
|||||||||
|
|
|
|
|
|||||||||||||||||||
|
3. |
To approve the Companys 2006 Directors Stock Option Plan, to replace the 1996 Directors Stock Option Plan, which is expiring. |
5. |
As said proxies deem advisable on such other matters as may come before the meeting and any adjournment(s) or postponement(s) thereof. |
|||||||||||||||||||
|
|
|
|
|
|||||||||||||||||||
|
|
o |
FOR |
o |
AGAINST |
o |
ABSTAIN |
|
o |
FOR |
o |
AGAINST |
o |
ABSTAIN |
|||||||||
|
|
|
|
|
|
||||||||||||||||||
|
|
|
|
|
PLEASE MARK, SIGN, DATE AND RETURN THE PROXY CARD IN THE ENCLOSED ENVELOPE. |
||||||||||||||||||
|
|
|
|
|
|
||||||||||||||||||
|
|
|
|
|
Note: This proxy should be marked, dated, signed by the stockholder(s) exactly as his or her name appears hereon, and returned in the enclosed envelope. |
||||||||||||||||||
|
|
|
|
|
|
||||||||||||||||||
|
|
|
|
|
Dated: __________________________ , 2006 |
||||||||||||||||||
|
|
|
|
|
|
||||||||||||||||||
|
|
|
|
|
|||||||||||||||||||
|
|
|
|
|
Signature(s) |
||||||||||||||||||
|
|
|
|
|
|
|
|||||||||||||||||
|
Please
sign exactly as name(s) appears hereon. When shares are held by joint
tenants, both should sign. When signing as attorney, executor, administrator,
trustee, or guardian, please give full title as such. If a corporation,
please sign in full corporate name by President or other authorized officer.
If a partnership, please sign in partnership name by authorized person. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS |
|
|
|
P |
|
|
|
|
|
R |
|
GERON CORPORATION |
|
|
|
O |
|
2006 ANNUAL MEETING OF STOCKHOLDERS |
|
|
|
X |
|
The undersigned stockholder of Geron Corporation, a Delaware corporation (the Company), hereby acknowledges receipt of the Notice of Annual Meeting of Stockholders and Proxy Statement, each dated April 3, 2006, and hereby appoints Thomas B. Okarma and David L. Greenwood, or any of them, as proxies and attorneys-in-fact with full power to each of substitution, on behalf and in the name of the undersigned to represent the undersigned at the 2006 Annual Meeting of Stockholders of Geron Corporation to be held on May 24, 2006, at 8:30 a.m. local time, at the Companys headquarters at 230 Constitution Drive, Menlo Park, CA 94025 and at any adjournment(s) or postponement(s) thereof, and to vote all shares of common stock that the undersigned would be entitled to vote if then and there personally present, on the matters set forth on the reverse side, and in their discretion, upon such other matter or matters that may properly come before the meeting and any adjournment(s) or postponement(s) thereof. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
This proxy will be voted as directed or, if no contrary direction is indicated, will be voted as follows: (1) for the election of three Class I Directors to hold office until the Annual Meeting of Stockholders in the year 2009; (2) to amend the Companys Restated Certificate of Incorporation to increase the number of authorized shares of the Companys Common Stock to 200,000,000 shares: (3) to approve the Companys 2006 Directors Stock Option Plan, to replace the 1996 Directors Stock Option Plan, which is expiring; (4) to ratify appointment of Ernst & Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2006; and as said proxies deem advisable on such other matters as may come before the meeting and any adjournment(s) or postponement(s) thereof. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CONTINUED AND TO BE SIGNED ON REVERSE SIDE |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
C5M;&YD8RF3!/HU%68MM?G( -@+I(B$KE)RP7*=PL"#Q8^I$;RH:=+8N]0\LOW/0`IA446T1IF_*9OD
MUUB]H=1?N)V#=&,*<6F&Y:FG:32.NV]JU%L'`Q6TQ"Z!J%Y2IG;?OD,M`Q[)
MOUIGY0ZMA79?N>I)D886SHC3/8[$$9%LH)C+3W$[!YQXC;@\I"A1:,N)#U[5
MN*E.9N*DY0.K,S:VK=H6,;4_+MK@EV(=*97\A2S?<]+9+EB,4U#:;M*^(_,3
MRD3/O<0L&@#"WS]8%)`C\PWK7VKE.Y^\@Z4V3>4>,-[;Y+==FE)J\ UWE0-[#*=K',]F*H0Q$_I&C)CC\H@*Y,
M):G(.C:W\O19;<$AX5!9JHL .[KA>L6!C@8Z:.Z+:BMLMLHEP2K%.E8JN=W,EDN2Y2
MSKL7CNZX7K&_S`QP,="Y=%M17)W)T2X)4=DNCM7.[F5.8YCJGT*$0+>D4U=W
M^```0!Y\YRNO-GU'0!M_@`````<`<<[`QTT=KNU%;9;96W@E6*=*Q4C[N9+)
MEKOG$15'CJT2\Y.#D(M$+EZJ"G=*X#X9U5L\41:7=&C
M6^NQAKRNW]/UH_D&R)_GM7+\PN/3]:/Y!LB?Y[5R_,+CT_6C^0;(G^>UV
MJ<7=T'Q-W/05K)GE"CWMS"XF@FA=%*521L^I9D'',?&2P5-&Y2\!Q,/EC0C(
M"P36.@R\MS\W)2H"*GD%.AE2N:U*I-H(`LV'"$.+&;;MQ<1PJ8GD>>$R-W:U
MR/1D',?>2P5''$39R$F'V)W/2!2)@K6\O+
E(F0.D4XFR$`)D@*:-S#(6\6="(3(QM*[,ZR@$,[?N@[NA6&:J
M8Z""OT;=+/V
'CD*BS
M:Z2@B'#.$,"IL;Q-Q-LDC1(-M[IK^H90QS<(*"$SIG8@$K1+PHTS\YD!)'AH
M:=R22NV7B5CR))!>G621EE+T:.Y>)%,A[H57R$()25"+C^\L!BIB0?6+^X?:
M"7)*%8M%:BPCH(#7;W%=;`M>;B&J-FPP[
`YFHR&Q&IJ1L]AKI"<8('LT?K
MNJW3-;D@71Y"`FU@V0%]LF';SE/:220800880\464\Z2442ZX^020^XIU\@A
M]U2W7GGG5*<==<4IQQQ2EK5E6